Plus Therapeutics Inc

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Plus Therapeutics advances trials, secures funding, and expands diagnostics

Plus Therapeutics demonstrates strong financial and operational progress with successful funding, grants, and trial advancements.
Strategic additions to the management team and diagnostic capabilities enhance the company's expertise and market positioning.
Challenges in financial management, regulatory processes, and dosing strategies require careful navigation for sustained growth and success.
Opportunities lie in FDA feedback, commercial launches, collaborations, and positive trial outcomes for future growth and market impact.

Plus Therapeutics Inc (PSTV) reports clinical progress amidst financial challenges

Plus Therapeutics Inc (PSTV) made significant clinical advancements in Q2 2024, while facing financial challenges. The company's strengths include positive trial results and supportive conference data, with opportunities for growth through expanded capabilities and funding access.

Plus Therapeutics progresses in leptomeningeal metastases program with strong financial backing

Plus Therapeutics is advancing promising treatments for leptomeningeal metastases with encouraging clinical data and FDA support.
Financially, the company is well-positioned with a solid cash balance, expected grant revenue, and access to diverse funding sources.
Strategic focus on upcoming events, milestones, and product launches underscores the company's commitment to innovation and growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breas

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Company to present ReSPECT-LM Phase 1 trial data on Rhenium ( 186 Re) Obisbemeda with a focus on treating leptomeningeal metastases (LM) in breast cancer patients AUSTIN, Texas, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, will present data at the 2024 San Antonio Breast Cancer Symposium, December 10-13, 2024 in San Antonio, Texas. Presentation: Title   Rhenium (186Re) obisbemeda (rhenium nanoliposome,186RNL) for the treatment of leptomeningeal metastases (LM): Update on Phase 1 dose escalation (Abstract Number: SESS-2271, Presentation ID: PS14-01)       Presenter   Andrew Brenner, M.D.

Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

AUSTIN, Texas, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics , Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on developing innovative radiotherapeutics, today announced the renewal of its Master Services Agreement (MSA) with Telix IsoTherapeutics Group Inc. (‘IsoTherapeutics', a Telix Group company). This MSA secures a reliable supply of cGMP Re-186, the radioisotope used in Plus Therapeutics' lead radiotherapeutic candidate Rhenium (186Re) Obisbemeda.

Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply

Single intrathecal dose of Rhenium ( 186 Re) Obisbemeda shows a favorable response rate and median overall survival in leptomeningeal metastases (LM) patients Achieves up to 8x absorbed radiation dose to the CNS subarachnoid space vs. standard of care external beam radiation Receives FDA agreement to initiate the ReSPECT-LM Phase 1 multiple administration dose escalation trial of Rhenium ( 186 Re) Obisbemeda for LM AUSTIN, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, presented data updating the progress of its ReSPECT-LM Phase 1 clinical trial of Rhenium (186Re) Obisbemeda (Rhenium Nanoliposome, 186RNL) in leptomeningeal disease (LM).

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference

Prospective FORESEE trial of CNSide Cerebrospinal Fluid (CSF) Assay met key primary and secondary endpoints CNSide CSF Assay influenced clinical management decisions in over 90% of leptomeningeal metastases (LM) cases Assay demonstrated 2.8 times the diagnostic sensitivity vs. standard cytology AUSTIN, Texas, Nov. 22, 2024 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), will present data from the FORESEE trial showcasing the CNSide CSF Assay Platform's utility in diagnosing and guiding clinical decision making for breast cancer and non-small cell lung cancer patients with LM.

Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases

CNSide Cerebrospinal Fluid (CSF) Assay analyzed 258 CSF samples across 66 leptomeningeal metastases (LM) patients at five institutions CNSide identified extensive, actionable mutational changes, and clinically relevant longitudinal biomarkers AUSTIN, Texas, Nov. 21, 2024 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), will present data demonstrating the utility of the CNSide CSF Assay Platform in identifying mutations of key biomarkers in the CSF and their implications in treatment selection for LM. The data will be presented at the 2024 Society for NeuroOncology (SNO) Annual Meeting November 21-24 in Houston, Texas.

Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases

Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q3 2024 Earnings Call Transcript November 14, 2024 5:00 PM ET Company Participants Marc Hedrick - President and CEO Andrew Sims - VP and CFO Conference Call Participants Justin Walsh - Jones Trading Edward Woo - Ascendiant Capital Sean Lee - H.C. Wainwright Operator Good afternoon, ladies and gentlemen.

Plus Therapeutics, Inc. (PSTV) Q3 2024 Earnings Call Transcript

Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium ( 186 Re) Obisbemeda for the treatment of patients with leptomeningeal metastases (LM) Presented positive ReSPECT-GBM Trial Data at the 2024 Congress of Neurological Surgeons Annual Conference Established Radiotherapeutic Manufacturing Partnership with SpectronRx to meet late-stage clinical and commercial forecasts for Rhenium ( 186 Re) Obisbemeda AUSTIN, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced financial results for the third quarter ended September 30, 2024, and provided an overview of recent and upcoming business highlights. Q3 2024 RECENT HIGHLIGHTS AND MILESTONES Completed enrollment in the Phase 1 ReSPECT-GBM trial Obtained agreement from FDA to begin enrollment in the ReSPECT-LM multi-administration trial for patients with LM (IND 153715).

Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

AUSTIN, Texas and INDIANAPOLIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics , Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics for central nervous system (CNS) cancers, and SpectronRx , a leading radiopharmaceutical contract developer and manufacturer, announced the signing of a Manufacturing Services Agreement (MSA) for the production of Rhenium (186Re) Obisbemeda, an innovative radiotherapy for CNS cancers, including leptomeningeal metastases and recurrent glioblastoma. “In 2025, we intend to begin late-stage clinical trials and are actively preparing for commercial level product demand, therefore now is the time to expand our supply chain and partner with leading radiopharmaceutical manufacturers such as SpectronRx that can deliver for us and our patients,” said Marc H.

Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership

AUSTIN, Texas, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report third quarter 2024 financial results on Thursday, November 14, 2024, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m.

Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024

Company will present results from the ReSPECT-LM Phase 1 clinical trial of Rhenium ( 186 Re) Obisbemeda for leptomeningeal metastases (LM) and discuss its plan for continued clinical development Company will present results from the FORESEE Trial of circulating tumors cells for improved diagnosis and disease monitoring of LM Company to host an educational symposium featuring clinical experts discussing LM and Plus' recent announcements for its LM therapeutic and diagnostic programs AUSTIN, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, will have multiple opportunities to present data at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting November 21-24, 2024 in Houston, Texas. Data presentations and symposium include: Presentations: Title Rhenium (186Re) Obisbemeda (rhenium nanoliposome,186RNL) for the treatment of leptomeningeal metastases (LM): Summary of the Phase 1 dose escalation study and Phase 2 administered dose selection (CTNI-63)     Presenter Andrew Brenner, M.D.

Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas

Rhenium ( 186 Re) Obisbemeda delivered by convection enhanced delivery (CED) continues to show safety, response, and potential efficacy Mean Phase 2 absorbed dose was 300 Gy and 89% of patients exceeded the minimal dose threshold of 100 Gy ReSPECT-GBM Phase 1/2 trial has expanded to two new sites at leading U.S. academic medical centers in New York and Upper Midwest AUSTIN, Texas, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers presented an update on the ongoing ReSPECT-GBM Phase 1/2 clinical trial, evaluating the Company's lead asset Rhenium (186Re) Obisbemeda for the treatment of recurrent glioblastoma. The data were presented at the 2024 Congress of Neurological Surgeons (CNS) Annual Meeting on September 30, 2024, in Houston, Texas.

Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting

AUSTIN, Texas, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, will present data at the 2024 Congress of Neurological Surgeons (CNS) Annual Meeting September 28 - October 2, in Houston, Texas.

Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting

AUSTIN, Texas, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that Marc H.

Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Plus Therapeutics, Inc. (PSTV) Q2 2024 Earnings Call Transcript

Presented Positive Interim ReSPECT-LM Phase 1 Data for Rhenium ( 186 Re) Obisbemeda for Leptomeningeal Metastases Presented Positive Topline Clinical Trial Results for CNSide diagnostic in the FORESEE trial Management to host conference call August 14, 2024 at 5:00 p.m. ET AUSTIN, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced financial results for the second quarter ended June 30, 2024, and provided an overview of recent and upcoming business highlights.

Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Plus' CNSide leptomeningeal metastases (LM) FORSEE trial met key primary and secondary endpoints CNSide more than doubled the diagnostic sensitivity vs. gold standard cerebral spinal fluid (CSF) cytology and influenced clinical management decisions in over 90% of LM cases AUSTIN, Texas, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, presented data from the FORESEE study of its CNSide platform for the diagnosis and management of LM.

Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference

Respect-LM dosing shows continued feasibility and safety of up to 44 mCi of intrathecal Rhenium ( 186 Re) Obisbemeda High absorbed radiation doses, mean circulating tumor cell reductions, and median overall survival of 12 months continue to show clinical promise AUSTIN, Texas, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, presented data in a podium presentation updating the progress of its ReSPECT-LM clinical trial of Rhenium (186Re) Obisbemeda (Rhenium Nanoliposome, 186RNL) in leptomeningeal disease (LM). The data were presented at the 2024 Society for NeuroOncology (SNO)/American Society for Clinical Oncology (ASCO) CNS Metastases Conference August 8-10, 2024 in Denver, Colorado.

Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference

AUSTIN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report second quarter 2024 financial results on Wednesday, August 14, 2024, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m.

Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024

AUSTIN, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, will have multiple opportunities to present data at the 2024 Society for Neuro-Oncology (SNO) / American Society for Clinical Oncology (ASCO) CNS Metastases Conference August 8-10, in Denver, Colorado. “This year's SNO/ASCO Metastases conference is a key opportunity for Plus to highlight advancements in our LM therapeutics and diagnostics programs,” said Marc H.

Plus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference

AUSTIN, Texas, July 02, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that Melissa Moore, Ph.D., Vice President, Clinical Research and Development, will give a presentation at 11:30 a.m.

Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer

Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center joins Plus as Vice President of Medical Affairs and Medical Director Plus receives notice of an additional $3.3 million CPRIT advance payment for leptomeningeal cancer targeted radiotherapeutic development program AUSTIN, Texas, June 07, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announced the appointment of Dr. Greg Fuller as the Company's Vice President of Medical Affairs and Medical Director.

Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT

AUSTIN, Texas, May 17, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that on May 8, 2024, it granted option awards to Charles Huang, the Company's new Director of Capital Markets and Investor Relations. The Company agreed to grant these equity awards to Mr.

Plus Therapeutics Announces New Employment Inducement Grants

Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q1 2024 Earnings Conference Call May 15, 2024 5:00 PM ET Company Participants Marc Hedrick - President and Chief Executive Officer Andrew Sims - Vice President and Chief Financial Officer Norman LaFrance - Senior Vice President and Chief Medical Officer Conference Call Participants Justin Walsh - Jones Trading Edward Woo - Ascendiant Capital Sean Lee - H.C. Wainwright Operator Good afternoon, ladies and gentlemen.

Plus Therapeutics, Inc. (PSTV) Q1 2024 Earnings Call Transcript

Announced private placement of up to $19.25M with healthcare funds and insiders Received $3M award recommendation from the Department of Defense to support Plus' clinical brain cancer program Acquired synergistic leptomeningeal metastases diagnostic portfolio and announced related positive top-line FORESEE clinical trial data Management to Host Conference Call May 15, 2024 at 5:00 p.m. ET AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc.  (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the first quarter ended March 31, 2024, and provided an overview of recent and upcoming business highlights.

News for Plus Therapeutics Inc Stock (PSTV)